Dermorphin vs BPC-157
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinRecovery & Repair
BPC-157- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- 4–6 hours
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- SubQ, IM, Oral
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 200–500 mcg
- Frequency
- Not established
- Once daily
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Stacks With
- —
- —